Abstract
Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.
| Original language | English |
|---|---|
| Pages (from-to) | 2043-2048 |
| Number of pages | 6 |
| Journal | Digestive diseases and sciences |
| Volume | 55 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2010 Jul 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Physiology
- Gastroenterology
Cite this
}
Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B. / Park, Yong Kwang; Lee, Jung Min; Kim, Do Young; Chang, Hye Young; Kim, Ja Kyung; Lee, Chun Kyon; Park, Jun Yong; Ahn, Sang Hoon; Lee, Kwan Sik; Han, Kwang Hyub.
In: Digestive diseases and sciences, Vol. 55, No. 7, 01.07.2010, p. 2043-2048.Research output: Contribution to journal › Article
TY - JOUR
T1 - Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B
AU - Park, Yong Kwang
AU - Lee, Jung Min
AU - Kim, Do Young
AU - Chang, Hye Young
AU - Kim, Ja Kyung
AU - Lee, Chun Kyon
AU - Park, Jun Yong
AU - Ahn, Sang Hoon
AU - Lee, Kwan Sik
AU - Han, Kwang Hyub
PY - 2010/7/1
Y1 - 2010/7/1
N2 - Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.
AB - Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.
UR - http://www.scopus.com/inward/record.url?scp=77954423985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954423985&partnerID=8YFLogxK
U2 - 10.1007/s10620-009-0983-1
DO - 10.1007/s10620-009-0983-1
M3 - Article
C2 - 19830555
AN - SCOPUS:77954423985
VL - 55
SP - 2043
EP - 2048
JO - American Journal of Digestive Diseases
JF - American Journal of Digestive Diseases
SN - 0002-9211
IS - 7
ER -